Adams, A. (1987). Replication of latent Epstein-Barr virus genomes in Raji cells. J Virol 61, 1743-1746.
Altmann, M., and Hammerschmidt, W. (2005). Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol 3, e404.
Babcock, G.J., Decker, L.L., Volk, M., and Thorley-Lawson, D.A. (1998). EBV persistence in memory B cells in vivo. Immunity 9, 395-404.
Battle-Lopez, A., Gonzalez De Villambrosia, S., Nunez, J., Cagigal, M.L., Montes- Moreno, S., Conde, E., and Piris, M.A. (2016). Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options. Expert Rev Anticancer Ther 16, 411-421.
Bhende, P.M., Seaman, W.T., Delecluse, H.J., and Kenney, S.C. (2004). The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat Genet 36, 1099-1104.
Chan, R.J., and Feng, G.S. (2007). PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109, 862-867.
Cohen, J.I. (2000). Epstein-Barr virus infection. N Engl J Med 343, 481-492.
Cohen, J.I., Fauci, A.S., Varmus, H., and Nabel, G.J. (2011). Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med 3, 107fs7.
Delecluse, H.J., Hilsendegen, T., Pich, D., Zeidler, R., and Hammerschmidt, W. (1998).Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci U S A 95, 8245-8250.
Djavadian, R., Hayes, M., and Johannsen, E. (2018). CAGE-seq analysis of Epstein- Barr virus lytic gene transcription: 3 kinetic classes from 2 mechanisms.PLoS Pathog 14, e1007114.
Farrell, P.J., Rowe, D.T., Rooney, C.M., and Kouzarides, T. (1989). Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J 8, 127-132.
Fernandez, A.F., Rosales, C., Lopez-Nieva, P., Grana, O., Ballestar, E., Ropero, S., Espada, J., Melo, S.A., Lujambio, A., Fraga, M.F., Pino, I., Javierre, B., Carmona, F.J., Acquadro, F., Steenbergen, R.D., Snijders, P.J., Meijer, C.J., Pineau, P., Dejean, A., Lloveras, B., Capella, G., Quer, J., Buti, M., Esteban, J.I., Allende, H., Rodriguez-Frias, F., Castellsague, X., Minarovits, J., Ponce, J., Capello, D., Gaidano, G., Cigudosa, J.C., Gomez-Lopez, G., Pisano, D.G., Valencia, A., Piris, M.A., Bosch, F.X., Cahir-Mcfarland, E., Kieff, E., and Esteller, M. (2009). The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 19, 438-451.
Hiscott, J., Kwon, H., and Genin, P. (2001). Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest 107, 143-151.
Holley-Guthrie, E.A., Quinlivan, E.B., Mar, E.C., and Kenney, S. (1990). The Epstein- Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J Virol 64, 3753-3759.
Hong, G.K., Kumar, P., Wang, L., Damania, B., Gulley, M.L., Delecluse, H.J., Polverini, P.J., and Kenney, S.C. (2005). Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol 79, 13984-13992.
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., and Yamanaka, S. (2009). Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460, 1132-1135.
Huang Da, W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57.
Inagaki, T., Sato, Y., Ito, J., Takaki, M., Okuno, Y., Yaguchi, M., Al Masud, H.M.A., Watanabe, T., Sato, K., Iwami, S., Murata, T., and Kimura, H. (2020). Direct evidence of abortive lytic infection-mediated establishment of Epstein-Barr virus latency during B-cell infection. bioRxiv, 2020.03.23.004440.
Iwami, S., Sato, K., De Boer, R.J., Aihara, K., Miura, T., and Koyanagi, Y. (2012).Identifying viral parameters from in vitro cell cultures. Front Microbiol 3, 319. Iwami, S., Takeuchi, J.S., Nakaoka, S., Mammano, F., Clavel, F., Inaba, H., Kobayashi,T., Misawa, N., Aihara, K., Koyanagi, Y., and Sato, K. (2015). Cell-to-cell infection by HIV contributes over half of virus infection. eLife 4, e08150.
Jha, H.C., Banerjee, S., and Robertson, E.S. (2016). The Role of Gammaherpesviruses in Cancer Pathogenesis. Pathogens 5, 18.
Jiang, S., Zhou, H., Liang, J., Gerdt, C., Wang, C., Ke, L., Schmidt, S.C.S., Narita, Y.,Ma, Y., Wang, S., Colson, T., Gewurz, B., Li, G., Kieff, E., and Zhao, B. (2017). The Epstein-Barr Virus Regulome in Lymphoblastoid Cells. Cell Host Microbe 22, 561-573.
Jochum, S., Moosmann, A., Lang, S., Hammerschmidt, W., and Zeidler, R. (2012a). The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS Pathog 8, e1002704.
Jochum, S., Ruiss, R., Moosmann, A., Hammerschmidt, W., and Zeidler, R. (2012b).RNAs in Epstein-Barr virions control early steps of infection. Proc Natl Acad Sci U S A 109, E1396-1404.
Kalla, M., Gobel, C., and Hammerschmidt, W. (2012). The lytic phase of epstein-barr virus requires a viral genome with 5-methylcytosine residues in CpG sites. J Virol 86, 447-458.
Kalla, M., Schmeinck, A., Bergbauer, M., Pich, D., and Hammerschmidt, W. (2010). AP- 1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc Natl Acad Sci U S A 107, 850-855.
Katsumura, K.R., Maruo, S., Wu, Y., Kanda, T., and Takada, K. (2009). Quantitative evaluation of the role of Epstein-Barr virus immediate-early protein BZLF1 in B-cell transformation. J Gen Virol 90, 2331-2341.
Konishi, N., Narita, Y., Hijioka, F., Masud, H., Sato, Y., Kimura, H., and Murata, T. (2018). BGLF2 Increases Infectivity of Epstein-Barr Virus by Activating AP-1 upon De Novo Infection. mSphere 3, e00138-18.
Kretzschmar, K., and Watt, F.M. (2012). Lineage tracing. Cell 148, 33-45.
Luka, J., Miller, G., Jornvall, H., and Pearson, G.R. (1986). Characterization of the restricted component of Epstein-Barr virus early antigens as a cytoplasmic filamentous protein. J Virol 58, 748-756.
Ma, S.D., Hegde, S., Young, K.H., Sullivan, R., Rajesh, D., Zhou, Y., Jankowska-Gan, E., Burlingham, W.J., Sun, X., Gulley, M.L., Tang, W., Gumperz, J.E., and Kenney,S.C. (2011). A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 85, 165-177.
Ma, Y., Walsh, M.J., Bernhardt, K., Ashbaugh, C.W., Trudeau, S.J., Ashbaugh, I.Y.,Jiang, S., Jiang, C., Zhao, B., Root, D.E., Doench, J.G., and Gewurz, B.E. (2017). CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors. Cell Host Microbe 21, 580-591.
Malmgaard, L. (2004). Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 24, 439-454.
Masud, H., Watanabe, T., Yoshida, M., Sato, Y., Goshima, F., Kimura, H., and Murata, T. (2017). Epstein-Barr Virus BKRF4 Gene Product Is Required for Efficient Progeny Production. J Virol 91, e00975-17.
Mcfadden, K., Hafez, A.Y., Kishton, R., Messinger, J.E., Nikitin, P.A., Rathmell, J.C., and Luftig, M.A. (2016). Metabolic stress is a barrier to Epstein-Barr virus- mediated B-cell immortalization. Proc Natl Acad Sci U S A 113, E782-790.
Mrozek-Gorska, P., Buschle, A., Pich, D., Schwarzmayr, T., Fechtner, R., Scialdone, A., and Hammerschmidt, W. (2019). Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection. Proc Natl Acad Sci U S A 116, 16046-16055.
Munz, C. (2019). Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat Rev Microbiol 17, 691-700.
Murata, T., Isomura, H., Yamashita, Y., Toyama, S., Sato, Y., Nakayama, S., Kudoh, A., Iwahori, S., Kanda, T., and Tsurumi, T. (2009). Efficient production of infectious viruses requires enzymatic activity of Epstein-Barr virus protein kinase. Virology 389, 75-81.
Murata, T., Okuno, Y., Sato, Y., Watanabe, T., and Kimura, H. (2019). Oncogenesis of CAEBV revealed: Intragenic deletions in the viral genome and leaky expression of lytic genes. Rev Med Virol, e2095.
Murayama, K., Nakayama, S., Kato-Murayama, M., Akasaka, R., Ohbayashi, N., Kamewari-Hayami, Y., Terada, T., Shirouzu, M., Tsurumi, T., and Yokoyama, S. (2009). Crystal structure of epstein-barr virus DNA polymerase processivity factor BMRF1. J Biol Chem 284, 35896-35905.
Nakayama, S., Murata, T., Yasui, Y., Murayama, K., Isomura, H., Kanda, T., and Tsurumi, T. (2010). Tetrameric ring formation of Epstein-Barr virus polymerase processivity factor is crucial for viral replication. J Virol 84, 12589-12598.
Okuno, Y., Murata, T., Sato, Y., Muramatsu, H., Ito, Y., Watanabe, T., Okuno, T., Murakami, N., Yoshida, K., Sawada, A., Inoue, M., Kawa, K., Seto, M., Ohshima, K., Shiraishi, Y., Chiba, K., Tanaka, H., Miyano, S., Narita, Y., Yoshida, M.,Goshima, F., Kawada, J.I., Nishida, T., Kiyoi, H., Kato, S., Nakamura, S., Morishima, S., Yoshikawa, T., Fujiwara, S., Shimizu, N., Isobe, Y., Noguchi, M., Kikuta, A., Iwatsuki, K., Takahashi, Y., Kojima, S., Ogawa, S., and Kimura, H. (2019). Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol 4, 404-413.
Perry, A.K., Chen, G., Zheng, D., Tang, H., and Cheng, G. (2005). The host type I interferon response to viral and bacterial infections. Cell Res 15, 407-422.
Pich, D., Mrozek-Gorska, P., Bouvet, M., Sugimoto, A., Akidil, E., Grundhoff, A., Hamperl, S., Ling, P.D., and Hammerschmidt, W. (2019). First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus. mBio 10, e01723-19.
Rooney, C.M., Rowe, D.T., Ragot, T., and Farrell, P.J. (1989). The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol 63, 3109-3116.
Sato, Y., Kamura, T., Shirata, N., Murata, T., Kudoh, A., Iwahori, S., Nakayama, S., Isomura, H., Nishiyama, Y., and Tsurumi, T. (2009). Degradation of Phosphorylated p53 by Viral Protein-ECS E3 Ligase Complex. PLoS Pathog 5, e1000530.
Sato, Y., Ochiai, S., Murata, T., Kanda, T., Goshima, F., and Kimura, H. (2017).Elimination of LMP1-expressing cells from a monolayer of gastric cancer AGS cells. Oncotarget 8, 39345-39355.
Sato, Y., and Tsurumi, T. (2010). Noise cancellation: viral fine tuning of the cellular environment for its own genome replication. PLoS Pathog 6, e1001158.
Sato, Y., Watanabe, T., Suzuki, C., Abe, Y., Masud, H., Inagaki, T., Yoshida, M., Suzuki, T., Goshima, F., Adachi, J., Tomonaga, T., Murata, T., and Kimura, H. (2019).S-Like-Phase Cyclin-Dependent Kinases Stabilize the Epstein-Barr Virus BDLF4 Protein To Temporally Control Late Gene Transcription. J Virol 93, e01707-18.
Shannon-Lowe, C., Rickinson, A.B., and Bell, A.I. (2017). Epstein-Barr virus- associated lymphomas. Philos Trans R Soc Lond B Biol Sci 372, 20160271.
Shimizu, N., Tanabe-Tochikura, A., Kuroiwa, Y., and Takada, K. (1994). Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol 68, 6069-6073.
Sugimoto, A., Sato, Y., Kanda, T., Murata, T., Narita, Y., Kawashima, D., Kimura, H., and Tsurumi, T. (2013). Different distributions of Epstein-Barr virus early and late gene transcripts within viral replication compartments. J Virol 87, 6693- 6699.
Tang, Y., Zhong, Y., Fu, T., Zhang, Y., Cheng, A., Dai, Y., Qu, J., and Gan, R. (2019). Bioinformatic analysis of differentially expressed genes and identification of key genes in EBV-transformed lymphoblasts. Biomed Pharmacother 116, 108984.
Tsurumi, T., Fujita, M., and Kudoh, A. (2005). Latent and lytic Epstein-Barr virus replication strategies. Rev Med Virol 15, 3-15.
Urier, G., Buisson, M., Chambard, P., and Sergeant, A. (1989). The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites. EMBO J 8, 1447-1453.
Vento-Tormo, R., Rodriguez-Ubreva, J., Lisio, L.D., Islam, A.B., Urquiza, J.M., Hernando, H., Lopez-Bigas, N., Shannon-Lowe, C., Martinez, N., Montes- Moreno, S., Piris, M.A., and Ballestar, E. (2014). NF-kappaB directly mediates epigenetic deregulation of common microRNAs in Epstein-Barr virus- mediated transformation of B-cells and in lymphomas. Nucleic Acids Res 42, 11025-11039.
Wang, C., Li, D., Zhang, L., Jiang, S., Liang, J., Narita, Y., Hou, I., Zhong, Q., Zheng, Z., Xiao, H., Gewurz, B.E., Teng, M., and Zhao, B. (2019). RNA Sequencing Analyses of Gene Expression during Epstein-Barr Virus Infection of Primary B Lymphocytes. J Virol 93, e00226-19.
Watanabe, T., Narita, Y., Yoshida, M., Sato, Y., Goshima, F., Kimura, H., and Murata, T. (2015). The Epstein-Barr Virus BDLF4 Gene Is Required for Efficient Expression of Viral Late Lytic Genes. J Virol 89, 10120-10124.
Wen, W., Iwakiri, D., Yamamoto, K., Maruo, S., Kanda, T., and Takada, K. (2007).Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. J Virol 81, 1037-1042.
Young, L.S., and Rickinson, A.B. (2004). Epstein-Barr virus: 40 years on. Nat Rev Cancer 4, 757-768.
Zhou, H., Schmidt, S.C., Jiang, S., Willox, B., Bernhardt, K., Liang, J., Johannsen, E.C., Kharchenko, P., Gewurz, B.E., Kieff, E., and Zhao, B. (2015). Epstein-Barr virus oncoprotein super-enhancers control B cell growth. Cell Host Microbe 17, 205-216.